.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

ADT and the Risk of Major Adverse Cardiovascular Events

EP. 1: Cardio-Oncology and Prostate Cancer

March 25th 2019

EP. 2: The Cardioprotective Role of Androgens

March 25th 2019

EP. 3: Adverse Effects of Hormone Therapy in Prostate Cancer

March 25th 2019

EP. 4: Data Supporting the Risk of MACEs in ADT

March 25th 2019

EP. 5: Effects of ADT on Morbidity and Mortality

March 25th 2019

EP. 6: GnRH Antagonists Versus GnRH Agonists

March 25th 2019

EP. 7: Real-World Patients With High Risk of MACEs

March 25th 2019

EP. 8: Standard of Care in Metastatic Prostate Cancer

March 25th 2019

EP. 9: Optimizing Prevention of MACEs in Prostate Cancer

March 25th 2019

EP. 10: ADT and the Need for a Multidisciplinary Approach

March 25th 2019